Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02183064
Recruitment Status : Completed
First Posted : July 8, 2014
Last Update Posted : July 8, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Study to compare the percentage of treatment successes or failures in patients randomized to meloxicam 7.5 mg vs. usual care prescription NSAIDs. Additionally, health care utilization, efficacy and safety of patients in a managed healthcare setting with osteoarthritis (OA) of the hip, knee, hand or spine will be assessed.

Condition or disease Intervention/treatment Phase
Osteoarthritis Drug: Meloxicam Drug: NSAID Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1309 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-Center, Randomized, Parallel-Group, Open-Label Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis of the Hip, Knee, Hand or Spine
Study Start Date : October 1998
Actual Primary Completion Date : November 2000

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis
Drug Information available for: Meloxicam

Arm Intervention/treatment
Experimental: Meloxicam Drug: Meloxicam
Active Comparator: Usual care prescription NSAID Drug: NSAID



Primary Outcome Measures :
  1. Percentage of treatment successes and failures in patients randomized to meloxicam 7.5 mg vs.usual care prescription NSAIDs [ Time Frame: up to 6 month ]

Secondary Outcome Measures :
  1. Investigator's Global Assessment of Disease Activity (Likert) [ Time Frame: Screening (Day 0), after six month (Day 180) ]
  2. Patient's overall Assessment of pain over the past week on a visual analogue scale (VAS) [ Time Frame: Day 0, 30, 60, 90, 120, 150, 180 ]
  3. Patient's Assessment of Health Status (VAS) [ Time Frame: Day 0, 30, 60, 90, 120, 150, 180 ]
  4. Patient's Assessment of Satisfaction of Health [ Time Frame: Day 0, 30, 60, 90, 120, 150, 180 ]
  5. Utility Index (VAS) [ Time Frame: Day 0, 30, 60, 90, 120, 150, 180 ]
  6. Western Ontario and Mc Master University Osteoarthritis Index (WOMAC) [ Time Frame: Day 0, 30, 60, 90, 120, 150, 180 ]
  7. Medication Compliance [ Time Frame: Day 30, day 180 ]
  8. Disability Index [ Time Frame: Screening (Day 0), after six month (Day 180) ]
  9. Permanent Discontinuation of Study Medication related to lack of efficacy [ Time Frame: up to day 180 ]
  10. Incidence and intensity of adverse events [ Time Frame: from day 30 until day 180 ]
  11. Permanent Discontinuation of Study Medication related to adverse event [ Time Frame: from day 30 until day 180 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males and females over the age of 18
  • The patient, if female and of reproductive potential (i.e. neither surgically sterilized nor post-menopausal), must be practicing adequate contraception (e.g. intrauterine device, contraceptive pills, Depo-Provera, or implant or double barrier device) for at least three months prior to and for the duration of their trial participation and must have a negative pregnancy test at screening. Abstinence is not considered to be an acceptable method of contraception. (It should be noted that NSAIDs might interfere with the effectiveness of intrauterine devices)
  • The patient must have a documented diagnosis of at least one of the following:

    • Osteoarthritis of the hip
    • Osteoarthritis of the knee
    • Osteoarthritis of the hand or
    • Osteoarthritis of the spine - Patients must have radiographic confirmation of the diagnosis
  • The patient is willing to change or requires a change in current prescription NSAID therapy or requires initiation of prescription NSAID therapy for treatment of OA of the hip, knee, hand or spine
  • The patient intends to remain a member of their present Managed Care Organization (MCO) for the duration of the trial
  • The patient is willing to comply with instructions and to provide written informed consent

Exclusion Criteria:

  • The patient has a known or suspected hypersensitivity to the trial drugs or their excipients, analgesics, antipyretics or NSAIDS (prescription or over-the-counter)
  • The patient has received an investigational drug or used an investigational device within 30 days prior to entering the trial
  • In the opinion of the investigator the patient has any disease or condition that may result in altered absorption, excess accumulation or impaired metabolism or excretion of the trial medication
  • The patient has a history of recurrent peptic ulcer or history (within the past 6 months) of gastrointestinal perforation, peptic ulceration documented by endoscopy or radiography, symptomatic hiatal hernia requiring daily treatment or any history of a gastrointestinal tract hemorrhage, except simple hemorrhoidal bleeding
  • The patient is currently on coumadin or might be placed on coumadin during the course of the clinical trial
  • Patients with dementia, i.e. incapable of following directions or complying with the study protocol
  • Patients with co-existing rheumatological disorders including rheumatoid arthritis
  • The patient has previously participated in this trial
  • Patients with coexisting fibromyalgia or ankylosing spondylitis
  • Patient is pregnant or lactating
  • Patient has severe hepatic failure
  • Patient has non-dialysed renal failure
  • Patient has history of GI bleed within the past 6 months
  • Patient has history of cerebrovascular bleeding or other bleeding disorders
  • Patient is receiving concomitant lithium, heparin or ticlopidine therapy
  • Patient has a history of leukopenia (White Blood Cell count < 3500/mm³)
  • The patient has a history of platelet count below the lower limit of normal or has a documented abnormal prothrombin time (PT) or partial thromboplastin time (PTT)

Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02183064     History of Changes
Other Study ID Numbers: 107.210
First Posted: July 8, 2014    Key Record Dates
Last Update Posted: July 8, 2014
Last Verified: July 2014

Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Meloxicam
Anti-Inflammatory Agents, Non-Steroidal
Anti-Inflammatory Agents
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antirheumatic Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action